Home
|
About Us
|
My Account
|
View Cart
|
Help
Company Info
About Us
Shipping
Terms and Conditions
Q1 Official Website
Home
>
Archived Webinars
>
340B Drug Pricing Program Challenges & New Developments for Manufacturers
Our Price:
$
395.00
Product Code:
WB-7116
Qty:
Product Info
About the Product
Includes 1 hour and 10 minute Windows Media Video File and PowerPoint presentations for immediate download.
The 340B Drug Pricing Program has been in effect for over twenty years, yet managed markets teams continue to face several challenges including Medicaid expansion, significant changes outlined in The Affordable Care Act and an evolving regulatory framework. To combat these regulatory challenges, the Health Resource & Service Administration (HRSA) previously announced they would reinforce existing guidance and issue a regulation which would narrow the reach of the drug discount program, termed the “mega-reg”. This guidance was scheduled to be released in 2014, but was officially pulled on November 13, 2014 in light of several legal challenges relating to other 340B regulations. While HRSA has stated they will issue new guidance on a broad range of 340B policy and practical issues in 2015, all stakeholders need to prepare for significant changes ahead.
Anticipated 2015 HRSA guidance and implications
Current and future regulatory oversight of 340B
HRSA’s role in 340B governance
Related case and outcomes analysis
Speaker:
John D. Shakow
Partner
King & Spalding
Participants that will find this webinar most beneficial will be those involved in pharmaceuticals companies. Job titles of attendees that will be most applicable for this session will be:
Pricing
Government Affairs
Managed Markets
Related Items
Overcoming Challenges Associated with Bundled Payments & Packaged Pricing
Pharmaceutical & Medical Device Advisory Committee Meeting Preparation & Management Series
Design & Execution of Clinical Studies to Support Device Reimbursement and Market Access
Pharma Regulatory Writing Webinar Series: Composition of Completed and Detailed CSRs and Narratives
Our Price:
$395.00
Our Price:
$795.00
Our Price:
$395.00
Our Price:
$395.00
Medical Device M&A: Current Due Diligence Issues including the Medical Device Tax and America Invents Act
Navigating Coding Structures Using Next Generation Sequencing to Determine Reimbursement
Tools and Techniques to Ensure Successful Outcomes in Clinical Device GCP Audits
Methods for Strengthening Medical Device Manufacturing Software Supplier Management
Our Price:
$395.00
Our Price:
$195.00
Our Price:
$395.00
Our Price:
$395.00
Share your knowledge of this product.
Be the first to write a review »